<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TEMOZOLOMIDE</span><br/>(tem-o-zol'o-mide)<br/><span class="topboxtradename">Temodar<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 20 mg, 100 mg, 250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Cytotoxic agent with alkylating properties structurally similar to dacarbazine. Effects are cell cycle nonspecific.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Interferes with purine (e.g. guanine) metabolism and thus protein synthesis in rapidly proliferating cells. Effectiveness
         is indicated by objective evidence of tumor regression.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adult patients with refractory anaplastic astrocytoma, glioblastoma multiforme with radiotherapy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to temozolomide, DTIC, or dacarbazine; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bacterial or viral infection; older adults; severe hepatic or renal impairment; myelosuppression; prior radiotherapy or chemotherapy.
         Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Astrocytoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150 mg/m<sup>2</sup> q.d. times 5 consecutive d per 28 d treatment cycle; subsequent doses are based on absolute neutrophil count on day 21 or
               at least 48 h before next scheduled cycle (see prescribing information for dosage adjustments based on neutrophil count)<br/><br/><span class="indicationtitle">Glioblastoma Multiforme</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75 mg/m<sup>2</sup> q.d. for 42 d with focal radiotherapy; after 4 wk, maintenance phase of 150 mg/m<sup>2</sup> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give consistently with regard to food.</li>
<li>Do not administer unless absolute neutrophil count &gt;1500 per microliter and platelet count &gt;100,000 per microliter.</li>
<li>Do not open capsules. Avoid inhalation or contact with skin or mucous membranes, if accidentally opened/damaged.</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Headache, fatigue, asthenia, fever,</span> back pain, myalgia, weight gain; viral infection. <span class="typehead">CNS:</span> <span class="speceff-common">Convulsions, hemiparesis, dizziness, abnormal coordination, amnesia, insomnia,</span> paresthesia, somnolence, paresis, ataxia, dysphasia, abnormal gait, confusion, anxiety, depression. <span class="typehead">CV:</span> <span class="speceff-common">Peripheral edema.</span> <span class="typehead">GI:</span> <span class="speceff-common">Nausea, vomiting, constipation, diarrhea,</span> abdominal pain, anorexia. <span class="typehead">Hematologic:</span> Anemia, <span class="speceff-both">neutropenia, thrombocytopenia,</span> leukopenia, lymphopenia. <span class="typehead">Respiratory:</span> Upper respiratory tract infection, pharyngitis, sinusitis, cough. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Metabolic:</span> Adrenal hypercorticism. <span class="typehead">Urogenital:</span> Urinary incontinence. <span class="typehead">Special Senses:</span> Diplopia, abnormal vision. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Valproic acid</b> may decrease <b>temozolomide</b> levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Metabolism:</span> Spontaneously metabolized to active metabolite MTIC. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 1.8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of toxicity: Infection, bleeding episodes, jaundice, rash, CNS disturbances.</li>
<li>Lab tests: CBC with differential on day 22 and weekly until absolute neutrophil count (ANC) &gt;1500 per microliter and platelet
            count &gt;100,000 per microliter; periodic liver function tests &amp; routine serum chemistry, including serum calcium.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take consistently with respect to meals.</li>
<li>Report to physician signs of infection, bleeding, discoloration of skin or skin rash, dizziness, lack of balance, or other
            bothersome side effects promptly.
         </li>
<li>Exercise caution with hazardous activities until response to drug is known.</li>
<li>Use effective methods of contraception; avoid pregnancy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>